Dermatitis News

BOSTON — Long-term use of tralokinumab showed sustained atopic dermatitis improvement with no new safety signals, according to a poster presented at the American Academy of Dermatology Annual Meeting.

Among systemic atopic dermatitis treatments, abrocitinib 200 mg and upadacitinib 30 mg had slightly better efficacy than dupilumab, according to a systemic review and network meta-analysis.

Autoimmune treatments accounted for more than half of all specialty drug growth in 2021, according to a drug trend report released by CVS Health.

More than 80% of patients with severe atopic dermatitis experienced significant improvement after treatment with upadacitinib compared with placebo, according to a study.

A Japanese study found difamilast ointment 1% to be efficacious and safe in the treatment of atopic dermatitis.

PHOENIX — Young children with atopic dermatitis demonstrated a significant disease burden impacting their quality of life, according to a study presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

Children with atopic dermatitis generally experienced the most intense itching in the early evening or bedtime, approximately 3 hours before they fell asleep, according to a study published in Annals of Allergy, Asthma & Immunology.

The development of asthma is more likely in patients with persistent or severe atopic dermatitis, according to a study.

Treatment with tralokinumab significantly improved symptoms among adolescents with moderate to severe atopic dermatitis, according to a study presented at the Western Society of Allergy, Asthma & Immunology Annual Scientific Meeting.

The FDA has accepted for priority review a supplemental biologics application for Dupixent that could allow treatment of moderate to severe atopic dermatitis in patients aged 6 months to 5 years, Regeneron announced in a press release.